Suspended PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00717652

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma (melasma)

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).

Sponsor: Azidus Brasil

Conditions Melasma

Interventions Triluma arbutin, tretinoin, triamcinolone

Updated 6 times since 2017 Last updated: Nov 1, 2022 Started: Jul 31, 2008 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

This trial was suspended. No reason was provided.

A PHASE2/PHASE3 clinical study on Melasma, this trial is suspended. The trial is conducted by Azidus Brasil and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2022 — Jul 2024 [monthly]

Suspended PHASE2_PHASE3
Jan 2021 — Dec 2022 [monthly]

Suspended PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Suspended PHASE2_PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azidus Brasil

Data source: Azidus Brasil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valinhos, Brazil